The core activity of MUGENBIO is the development of biotechnological solutions for the earlier and more accurate diagnosis of cancer, particularly prostate cancer. The company focuses on developing a platform for diagnosing prostate cancer based on three innovative pillars, aiming to improve existing diagnostic methods and enable early detection of prostate cancer.
AI-generated
Offering
Products & services
Industry:Medical Technology Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Next-generation diagnostic platform for prostate cancer with ultrasensitive molecular biomarker quantification, a diagnostic device for 100+ biomarkers, and AI data analysis.
Comparisons
MUGENBIO GmbH in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank MUGENBIO GmbH by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once MUGENBIO GmbH has claimed this profile, we'll publish editorial articles and case studies here together.